Abstract
RESUME: Background: Capecitabine is an oral fluoropyrimidine carbamate that is at least as effective than Fluorouracil / Leucovorin as first- line treatment for patients with metastatic colorectal cancer /CRC/. Aim: The aim of this study was to evaluate the efficacy and toxicity of single- agent Capecitabine as first- line therapy in patients with metastatic CRC. Methods: In the period 2007- 2009 17 consecutive patients with /CRC/ entered the study. The treatment schedule consists of Capecitabine 1250 mg/m 2 p.o. twice daily for 14 days with a 7- day rest period. Results: Overall response rate was 23,6% with one complete remission. Median survival was 12,4 months. Nausea, vomiting and diarrhea were the most common side effects. Conclusions: That data suggest that singleagent Capecitabine will offer opportunity to treat patients with advanced /CRC/.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of IMAB - Annual Proceeding (Scientific Papers)
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
